| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Other Income | ₹0.64 | ₹0.00 | ₹0.01 | ₹0.00 |
| Total Revenue | ₹0.64 | ₹0.00 | ₹0.01 | ₹0.00 |
| Total Expenses | ₹1.73 | ₹0.74 | ₹0.34 | ₹0.19 |
| Profit Before Tax | -₹1.09 | -₹0.74 | -₹0.34 | -₹0.19 |
| Tax | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | -₹1.09 | -₹0.74 | -₹0.34 | -₹0.19 |
| EPS - Basic | -₹0.99 | -₹1.68 | -₹0.77 | -₹0.42 |
| EPS - Diluted | -₹0.99 | -₹1.68 | -₹0.77 | -₹0.42 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹1.09 | -₹0.74 | -₹0.34 | -₹0.19 |
| Income before WC changes | -₹1.08 | -₹0.74 | -₹0.34 | -₹0.18 |
| Change in Assets | -₹1.99 | -₹1.20 | ₹0.03 | ₹0.65 |
| Change in Liabilities | -₹1.64 | ₹1.73 | -₹0.04 | -₹0.61 |
| Change in WC | -₹3.63 | ₹0.53 | -₹0.02 | ₹0.04 |
| Cash flow from Operations | -₹4.71 | -₹0.21 | -₹0.35 | -₹0.13 |
| Cash flow from Investing | -₹0.05 | ₹0.00 | ₹0.00 | ₹0.00 |
| Cash flow from Financing | ₹23.39 | ₹2.88 | ₹0.36 | ₹0.13 |
| Total Cash Flow | ₹18.63 | ₹2.67 | ₹0.00 | -₹0.01 |
| Cash (Start of the year) | ₹2.67 | ₹0.00 | ₹0.00 | ₹0.01 |
| Cash (End of the year) | ₹21.30 | ₹2.67 | ₹0.00 | ₹0.00 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹0.07 | ₹0.02 | ₹0.02 | ₹0.02 |
| Current Assets | ₹25.16 | ₹4.55 | ₹0.68 | ₹0.71 |
| Total Assets | ₹25.23 | ₹4.57 | ₹0.70 | ₹0.73 |
| Current Liabilities | ₹0.57 | ₹3.49 | ₹1.43 | ₹1.12 |
| Net Current Asset | ₹24.59 | ₹1.06 | -₹0.75 | -₹0.42 |
| Non-Current Liabilities | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Equity Capital | ₹24.65 | ₹1.08 | -₹0.73 | -₹0.39 |
| Total Equity & Liabilities | ₹25.23 | ₹4.57 | ₹0.70 | ₹0.73 |
KABRA DRUGS LTD. share price is ₹22.93 as on 03 Jul, 2026, 15:51 IST.
In the last 1 year, KABRA DRUGS LTD. delivered a return of 27.39%. The KABRA DRUGS LTD. share price hit a high of ₹35.52 and low of ₹15.50.
The Mutual Fund Shareholding in KABRA DRUGS LTD. was 0.00% at the end of Mar 2026.
The 52-week high and low of KABRA DRUGS LTD. share is ₹35.52 and ₹15.50 as of 03 Jul, 2026.
The market capitalisation of KABRA DRUGS LTD. is ₹55.24 Crores as on 03 Jul, 2026.
The stock symbol of KABRA DRUGS LTD. is 524322 on the BSE, and the ISIN is INE323K01017.
KABRA DRUGS LTD. shares closed yesterday at ₹23.30 on BSE
To buy KABRA DRUGS LTD. shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of KABRA DRUGS LTD. or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell KABRA DRUGS LTD. shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of KABRA DRUGS LTD. is 11.15 and 1.87 respectively, as on 03 Jul, 2026, 15:51 IST.